BBP
Virtus LifeSci Biotech Products ETF
Price Chart
Latest Quote
$103.92
+1.59 (+1.55%)
Current Price
| Previous Close | $102.33 |
| Open | $102.39 |
| Day High | $104.28 |
| Day Low | $102.36 |
| Volume | 5,162 |
Fund Information
| Net Assets | $131.53M |
| Expense Ratio | 0.34% |
| Category | Health |
| Fund Family | Virtus |
| Net Asset Value | $102.39 |
| Premium/Discount | 1.49% |
| Exchange | PCX |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $102.98 |
| SMA50 | $104.80 |
| SMA200 | $92.12 |
| RSI | 53.84 |
| ATR | 2.6583 |
| Rel Volume | 0.36 |
Performance History
| Week | -1.78% |
| Month | -1.04% |
| Quarter | +7.47% |
| 6 Months | +24.44% |
| YTD | +30.42% |
| Year | +43.25% |
| 3 Years | +121.13% |
| 5 Years | +107.64% |
| 10 Years | +255.38% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $103.92 | 5,162 |
| 2026-10-26 | $102.33 | 9,400 |
| 2026-10-23 | $102.07 | 9,800 |
| 2026-10-22 | $103.96 | 10,000 |
| 2026-10-21 | $104.94 | 11,600 |
| 2026-10-20 | $105.80 | 10,200 |
| 2026-10-19 | $102.38 | 14,000 |
| 2026-10-16 | $100.20 | 30,600 |
| 2026-10-15 | $104.56 | 14,600 |
| 2026-10-14 | $101.80 | 16,000 |
| 2026-10-13 | $100.71 | 12,300 |
| 2026-10-12 | $103.63 | 7,700 |
| 2026-10-09 | $104.76 | 8,900 |
| 2026-10-08 | $101.24 | 12,500 |
| 2026-10-07 | $101.81 | 6,200 |
| 2026-10-06 | $100.97 | 16,300 |
| 2026-10-05 | $103.33 | 31,200 |
| 2026-10-02 | $102.50 | 18,700 |
| 2026-10-01 | $103.21 | 25,100 |
| 2026-09-30 | $105.59 | 13,600 |
| 2026-09-29 | $106.29 | 21,500 |
| 2026-09-28 | $105.02 | 17,400 |
About Virtus LifeSci Biotech Products ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.
đ° Latest News
No news articles available at the moment. Check back later for updates on BBP.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.